Search Orphan Drug Designations and Approvals
-
Generic Name: | 2-[(3S)-2,6-dioxopiperidin-3-yl]-4-{[(2-fluoro-4-{[3-(morpholin-4-yl)azetidin-1-yl]methyl} phenyl) methyl]amino}-1H-isoindole-1,3(2H)-dione-hydrogen chloride (1/1) |
---|---|
Date Designated: | 01/25/2023 |
Orphan Designation: | Treatment of Follicular Lymphoma (FL) |
Orphan Designation Status: | Designated |
FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
Sponsor: |
Celgene Coporation 86 Morris Avenue Summit, New Jersey 07901 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-